Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Maintains Outperform on S&P Global, Raises Price Target to $402

Raymond James analyst Patrick O'Shaughnessy maintains S&P Global (NYSE:SPGI) with a Outperform and raises the price target from $398 to $402.
byBenzinga Newsdesk
February 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Raymond James analyst Patrick O’Shaughnessy maintains S&P Global (NYSE:SPGI) with a Outperform and raises the price target from $398 to $402.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Ocular Therapeutix Announced Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD; Said 80% of Subjects were Rescue-Free up to 6 months and 73% of Subjects Were Rescue-Free up to 7 months Following a Single OTX-…

By Charles Gross
September 27, 6:02 AM
Ocular Therapeutix, Inc. (NASDAQ: OCUL) today announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company's axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.

OCUL